Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Karyopharm Therapeutics (KPTI) Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in PFSl in Patients with Unresectable Dedifferentiated Liposarcoma
November 2, 2020 4:03 PM ESTKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 portion of the randomized, double blind, placebo controlled, cross-over, SEAL study evaluating single agent, oral XPOVIO® (selinexor) versus matching placebo in patients with advanced unresectable dedifferentiated liposarcoma. The SEAL study met its primary endpoint of a statistically significant increase in progression-free survival (PFS); hazard ratio=0.70; p=0.023. These data indicate that treatment with XPOVIO reduced the risk of disease progression or death by approximately 30%, compared to placebo. The trial allowed patients on placebo... More
Karyopharm Therapeutics (KPTI) Halted, News Pending
November 2, 2020 4:00 PM ESTKaryopharm Therapeutics (NASDAQ: KPTI) Halted, News Pending
